Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderately to severely active rheumatoid arthritis. Sold as Rinvoq, Rinvoq Lq. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 16, 2026, FDA lists 4 applications for Upadacitinib (sold as Rinvoq, Rinvoq Lq), first approved Aug 16, 2019, with 11 new uses approved and 0 published complete response letters.
First approved: Aug 16, 2019
Applications: 4
New uses approved: 11
Complete response letters: 0
Medicare spending, 2025: $2.36B
Orphan exclusivity until: Apr 28, 2032
First approved in the EU: Dec 16, 2019
First approved in Japan: Jan 23, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 5 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
RinvoqDrugs with a new indication and a new dosage for the treatment of giant cell arteritis in patients who have not responded sufficiently to conventional… · AbbVie GK · Jun 24, 2025
RinvoqDrugs with a new additional pediatric dosage indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to… · AbbVie GK · Sep 24, 2024
Rinvoq(1) (2) (3) Drugs with a new indication and a new dosage for the remission induction therapy and the maintenance therapy of moderate to severe active… · AbbVie GK · Jun 26, 2023
RinvoqDrugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently… · AbbVie GK · Feb 24, 2023
Rinvoq(1) (2) (3) Drugs with a new indication and a new dosage for the remission induction and maintenance therapy of moderate to severe ulcerative colitis (for… · AbbVie GK · Sep 26, 2022
RinvoqDrugs with a new indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional… · AbbVie GK · May 26, 2022
Rinvoq, new approvalA drug in an additional dosage form indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. · AbbVie GK · Sep 27, 2021 · Review report
RinvoqDrugs with a new indication and a new dosage for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. · AbbVie GK · Aug 25, 2021
Clinical Trials
91 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA